cordis coronary stent

Wilson, G. J. et al. 38, 10341043 (2017). Receive the the latest news, research, and presentations from major meetings right to your inbox. Angioplasty uses a tiny balloon catheter that is inserted in a blocked blood vessel to help widen it and improve blood flow to the heart. Covid19 was positive in 16 cases by RT PCR. government site. For more information about Cordis please visit: www.cordis.com (this site is intended for US visitors only). Am. Nakazawa, G. et al. Sciahbasi, A. et al. J. Vasc. The company will continue to focus on cardiovascular care through its Biosense Webster and Cordis businesses: Biosense Webster will continue to build and expand on its global leadership position in the $2.5 billion electrophysiology (EP) market, as an innovative provider of advanced cardiac diagnostic, therapeutic, and mapping tools. 165, 415420 (2013). Otsuka, F. et al. Circulation 129, 211223 (2014). Kuroda, M. et al. & Webster, M. W. Stent longitudinal integrity bench insights into a clinical problem. Coll. Coll. wrote the manuscript. 8600 Rockville Pike Comparison of vascular response between durable and biodegradable polymer-based drug-eluting stents in a porcine coronary artery model. R.V. Scientific Reports Cardiol. Richard Grimes, Andrew Beall, and Jeremy Harman formed the contemporary ensemble, CORDIS, in Boston, MA in 2008. Groin haematoma was seen in five cases requiring one unit of blood transfusion. Res. To safely perform angioplasties in acute coronary syndromes with very low contrast volume using Cordis diagnostic catheters and thereby improve the cardiovascular and renal outcomes. / PRNewswire / -- Cardinal Health today announced that it has entered into a distribution agreement with Biosensors that enables Cordis, Cardinal Health's interventional vascular business, to sell Biosensors' coronary stent portfolio. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Over-the-Wire coronary stent. Proc. Please click below to continue to that site. Circulation 139, 325333 (2019). Med. As the leader in EP navigation systems and ablation therapy, Biosense Webster, Inc. has technology that includes the largest installed base of cardiac mapping navigation systems worldwide in leading hospitals and teaching institutions. In 2000, patients were enrolled in the RAVEL Trial, the first multi-center, randomized, double-blind, trial in history for drug-eluting stents. Lancet 380, 14821490 (2012). Cordis Corporation, a Johnson & Johnson company, specializes in the development and manufacture of interventional vascular technology. Am. Sakamoto, A., Jinnouchi, H., Torii, S., Virmani, R. & Finn, A. V. Understanding the impact of stent and scaffold material and strut design on coronary artery thrombosis from the basic and clinical points of view. The sirolimus helps limit the overgrowth of normal cells while the artery heals. Mit Ihrer Anmeldung erklren Sie sich damit einverstanden, Inhalte von uns zu erhalten. PubMed Central Nat Rev Cardiol 17, 3751 (2020). 26 deaths in total were observed in this series; 16 of these patients had cardiogenic shock (7 late presenters), and three patients expired after discharge due to possible acute stent thrombosis. El-Hayek, G. et al. , . Interv. The company will continue to focus on cardiovascular care through its Biosense Webster and Cordis businesses: Biosense Webster will continue to build and expand on its global leadership position in the $2.5 billion electrophysiology (EP) market, as an innovative provider of advanced cardiac diagnostic, therapeutic, and mapping tools. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Acute thrombogenicity of a durable polymer everolimus-eluting stent relative to contemporary drug-eluting stents with biodegradable polymer coatings assessed ex vivo in a swine shunt model. Optical coherence tomography findings in patients with coronary stent thrombosis: a report of the PRESTIGE Consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort). When typing in this field, a list of search results will appear and be automatically updated as you type. Heart J. Cardiovasc. 67, 751762 (2016). has received honoraria from Abbott Vascular, Biosensors, Boston Scientific, Celonova, Cook Medical, Cordis, CSI, Lutonix Bard, Medtronic, OrbusNeich Medical, CeloNova, SINO Medical Technology, ReCore, Spectranetics, Terumo Corporation and W. L. Gore. Cardiol. Chichareon, P. et al. Yazdani, S. K. et al. Sign up for the Nature Briefing newsletter what matters in science, free to your inbox daily. S.T., H.J., A.S., A.C., H.M., D.C., M.E.R., F.D.K., A.G., R.V. In a history of impressive CYPHER(R) stent data announcements at ESC in Stockholm, Marie Claude Morice, M.D., Institut Cardiovasculaire Paris Sud, had presented the initial results of the highly successful RAVEL trial, the first CYPHER(R) stent randomized trial, at the Annual Congress of the European Society of Cardiology in 2001. Summary of risk estimates for secondary outcomes with early aspirin discontinuation vs dual antiplatelet therapy after coronary stenting. Nakazawa, G. et al. Never before have cardiologists been faced with so many choices of stent, each with its own unique design. 70 patients had cardiogenic shock at presentation. By PBR Staff Writer. Lancet 390, 781792 (2017). CAS 48, 193202 (2006). Am. 10, 688700 (2014). Cite this: Cordis Quits Stent Business, Dropping Cypher, Nevo DES-Medscape-Jun16,2011. Nakazawa, G. et al. 38, 22172224 (2018). PubMed Coll. Surg. Interv. Cordis will expand its portfolio of vascular solutions for endovascular and cardiology procedures, a $12 billion market. You must declare any conflicts of interest related to your comments and responses. Catheter. , , , , , , Environmental, Social and Governance (ESG), HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American. 9, e003785 (2016). Unlicensed competition from products that infringe Cordis patents, both owned and licensed, has eroded CYPHER Stent pricing, sales and market share, and has dampened the prospects for NEVO Stent commercialization. For more information about Biosense Webster and its products, please visit: www.biosensewebster.com (this site is intended for US visitors only). Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Provided by the Springer Nature SharedIt content-sharing initiative, Cardiovascular Intervention and Therapeutics (2023), Journal of Thrombosis and Thrombolysis (2022), Nature Reviews Cardiology (Nat Rev Cardiol) CYPHER's(R) body of clinical evidence is completely unmatched by any other drug-eluting stent. These statements are based on current expectations of future events. Implantation of drug-eluting stents (DES) is the main treatment strategy for patients with coronary artery disease. Plot of hazard ratio for stent thrombosis (A), stroke (B), and major bleeding (C) associated with early aspirin discontinuation (experimental therapy) vs dual antiplatelet therapy (control therapy). This is an impressive outcome and a testament to the efficacy of the CYPHER(R) stent. Interv. R.V. Van der Heiden, K. et al. CAS Finn, A. V. et al. volume17,pages 3751 (2020)Cite this article. Am. Cardiol. 21 June 2022, Nature Communications Characteristics of earlier versus delayed presentation of very late drug-eluting stent thrombosis: an optical coherence tomographic study. Coll. The company will also stop the manufacture of CYPHER and CYPHER SELECT Plus Sirolimus-Eluting Coronary Stents by the end of 2011. Habib, A. et al. Aloke V. Finn. A variety of coronary stents from various companies were used. Implantation of drug-eluting stents (DES) is the dominant treatment strategy for patients with symptomatic coronary artery disease. Int. Get the most important science stories of the day, free in your inbox. The patient, who was treated in 1999 with the CYPHER(R) stent at the age of 75 after her coronary angiography showed a significant, single, de novo lesion in the proximal left anterior descending (LAD) artery, under-went further invasive follow-up revealing a sustained anti-proliferative effect of the CYPHER(R) stent by both angiography and IVUS examination in 2009. JACC Cardiovasc. Otsuka, F. et al. Varenne, O. et al. Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed? Neither Cordis Corporation nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.). Medication coats drug-eluting stents and reduces the chance of renarrowing, or restenosis, of the blood vessel. The company intends to close two manufacturing facilities: Cashel, Ireland, where the NEVO Stent was to be produced, and San German, Puerto Rico, the manufacturing site for the CYPHER Stent products. 3, 174183 (2010). Explaining the company's decision, Cordis group chair and worldwide chair Seth Fischer stated, "Due to evolving market dynamics in the drug-eluting stent business, we see greater opportunities to benefit patients and grow our business in other areas of the cardiovascular-device market.". Kolandaivelu, K. et al. J.Med. Cision Distribution 888-776-0942 3,39-41 These ex vivo studies demonstrated a lack of . All material on this website is protected by copyright, Copyright 1994-2023 by WebMD LLC. TCTMD is produced by the Cardiovascular Research Foundation (CRF). The results from this trial surpassed expectations, demonstrating virtual elimination of neointimal in-stent proliferation with no measurable late loss (-0.01mm), a binary angiographic restenosis rate of 0%, and no acute or late stent thrombosis. BRIDGEWATER, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced it will no longer pursue the development of the NEVO Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies where significant patient need exists. HHS Vulnerability Disclosure, Help Circulation 103, 28162821 (2001). "Cordis has been a leader in establishing many markets including diagnostic and guiding catheters, bare metal and drug-eluting stents, carotid stenting, and treatment of peripheral vascular disease and arrhythmias. Today, with more than 9.000 citations on PubMed, CYPHER(R) Sirolimus-eluting coronary stent is recognized as having the most in depth clinical data, which marked it out as the most effective drug-eluting stent available today with a safety profile presenting minimal risks. Leon MB, Baim DS, et al. You are using a browser version with limited support for CSS. Comparison of in vivo longitudinal strength and conformability following stent implantation in rabbit iliac artery. Arterioscler. Comparison of the endothelial coverage in everolimus and zotarolimus-eluting stents in normal, atherosclerotic, and bifurcation rabbit iliac arteries. 33, 24252431 (2013). 12, 1 (2015). Oncogenesis 6, e311 (2017). Mori, H. et al. Torii, S. et al. J. Cardiol. Overall, the company expects to reduce 900 - 1,000 positions, subject to any consultation procedures on these plans in countries where required. Cardiol. Please confirm that you would like to log out of Medscape. The Nevo stent, meanwhile, the sirolimus-loaded version of the failed Conor stent, was supposed to be an answer to the indiscriminate drug delivery offered by existing DES, because its novel design used little reservoirs filled with sirolimus and polymer, rather than coating the entire stent with the drug. Vranckx, P. et al. In a separate news release today, Cordis parent company, Johnson & Johnson, announced the financial implications of Cordis restructuring plans. Cardiovasc. reviewed and edited the manuscript before submission. Otsuka, F. et al. Coronary artery disease and stable angina, Histopathological evaluation of a retinoic acid eluting stent in a rabbit iliac artery model, Five-Year Impacts of Antithrombotic Therapy Based on 10-Year Clinical Outcomes of Cypher Stent Implantation, A tough nitric oxide-eluting hydrogel coating suppresses neointimal hyperplasia on vascular stent, Histological evaluation of vascular changes after excimer laser angioplasty for neointimal formation after bare-metal stent implantation in rabbit iliac arteries. Cardiol. The pleiotropic regulation of cyclin D1 by newly identified sesaminol-binding protein ANT2. Interv. Interv. Nakano, M. et al. J. Cardiol. Huynh, K. Antiplatelet therapy: risks and benefits of extended DAPT after stenting. Cardiol. The CYPHER(R) stent is the most studied drug-eluting stent in the world, it has a proven safety profile out to 10 years and has been used in nearly 4 million patients worldwide. Bridgewater, NJ (June 15, 2011) -- Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced it will no longer pursue the development of the NEVO Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies where significant patient need exists. More recently, ex vivo study has been conducted on several of the more commonly used coronary drug-eluting stents, including 2005 to 2006 versions of the Cypher (Johnson & Johnson/Cordis), Taxus Express (Boston Scientific), Taxus Liberte (Boston Scientific), and Endeavor (Medtronic) stents. Introduction and aims: Difficulty in engaging with guide catheters is not uncommon in acute emergencies. 19, 818819 (2018). Interv. Imaging 8, 451460 (2015). Ten-year clinical outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease. "Due to evolving market dynamics in the drug-eluting stent (DES) business, we see greater opportunities to benefit patients and grow our business in other areas of the cardiovascular device market," said Seth Fischer, Company Group Chair and Worldwide Chairman, Cordis Corporation. Coll. In fact, the CYPHER(R) stent has shown more than 70% risk reduction in target lesion revascularization (TLR) when compared with bare metal stents. Byrne, R. A., Stone, G. W., Ormiston, J. Nature Reviews Cardiology The business will focus on access, diagnostic and therapeutic products for cardiology procedures, products to diagnose, access and treat lower extremity disease, and the INCRAFT Stent-Graft System, the companys new investigational device for treating abdominal aortic aneurysm (AAA). is a consultant for Amgen, Abbott Vascular, Boston Scientific, Celonova, Cook Medical, Lutonix Bard and Sinomed. TCTMD All rights reserved. For over 60 years, we've pioneered products. Heart Assoc. Accuracy of OCT, grayscale IVUS, and their combination for the diagnosis of coronary TCFA: an ex vivo validation study. Interv. Recent advances in drug eluting stents. Early experience with the CYPHER stent has shown that stent thrombosis occurs in 0.5% of patients. Nat. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. STACCATO (Assessment of Stent sTrut Apposition and Coverage in Coronary ArTeries with Optical coherence tomography in patients with STEMI, NSTEMI and stable/unstable angina undergoing everolimus versus biolimus A9-eluting stent implantation): a randomised controlled trial. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Adriaenssens, T. et al. Heart J. Qual. Palmerini, T. et al. Mehilli, J. et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. The company will also stop the manufacture of CYPHER and CYPHER SELECT Plus Sirolimus-Eluting Coronary Stents by the end of 2011. But as Simon observed, the timing of the Cypher's demise is "ironic," coming as it does on the heels of trial results like EXCELLENT and SORT-OUT 4, which have suggested equivalency between the Cypher and Xience stents. Contract & Freelance Partner Opportunities, Do Not Sell or Share My Personal Information, Limit the Use of My Sensitive Personal Information. All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. Joner, M. et al. BMJ 350, h1618 (2015). J. Invasive Cardiol. Together, these businesses share the common goal of providing lasting and minimally invasive treatments to improve and extend the lives of patients suffering from cardiovascular disease. 25, 383390 (2013). Torii, S. et al. Hasebe, T. et al. [1] The group was created as a performance vehicle for Grimes' compositions. These businesses generated 2010 sales of $1.9 billion*, representing an operational growth rate of 8 percent versus the prior year. An uncommon but important cause of stent thrombosis: Kounis syndrome. The company intends to close two manufacturing facilities: Cashel, Ireland, where the NEVO Stent was to be produced, and San German, Puerto Rico, the manufacturing site for the CYPHER Stent products. 92, 253259 (2018). Ninety one patients had creatinine more than 2mg/dl before the angioplasty procedures. All contrast injections were given by hand. Gomez-Lara, J. et al. She studied literature at McGill University and the University of Cape Town and received her graduate degree in journalism from the University of British Columbia, specializing in health reporting. Interv. Circ. ISSN 1759-5002 (print). A., Webber, B. 36, 21472159 (2015). Cardiol. The 85-year-old patient was the first-ever patient to be treated with a CYPHER(R) stent and made history by undergoing the longest term follow-up, ten years later. 10-year clinical outcome after randomization to treatment by sirolimus- or paclitaxel-eluting coronary stents. Neither Cordis Corporation nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments. Cardiovasc. Ann. Sabate, M. et al. Coronary angioplasty (AN-jee-o-plas-tee), also called percutaneous coronary intervention, is a procedure used to open clogged heart arteries. Navarese, E. P. et al. , . Enter the email you used to register to reset your password. Circulation 120, 141149 (2009). The effects of stenting on shear stress: relevance to endothelial injury and repair. The company will also consolidate its Research and Development project teams in Fremont, California. Cordis Unveils CoCr Coronary Stent. EuroIntervention 14, 16851693 (2018). Am. 36, 10311039 (2002). "To think this has happened from 2003 to the present: it's hard to find words for it. All contrast injections were given by hand. Rev. Jensen, L. O. et al. Med. Eur. Eppihimer, M. J. et al. Developed and manufactured by Cordis Corporation, the CYPHER(R) Stent is currently available in more than 80 countries and has the broadest clinical experience and longest-term clinical follow-up of any drug-eluting stent. Am. . 441, 665679 (2013). Through the company's innovation, research and development, Cordis works with interventional cardiologists, interventional radiologists and vascular surgeons worldwide to treat millions of patients who suffer from vascular disease. Please select your country to continue. Presented at the Transcatheter Cardiovascular Therapeutics meeting (TCT 2018). EuroIntervention 14, 11291135 (2018). En vous inscrivant la newsletter, vous consentez la rception de contenus de notre part. Mauri, L. et al. Join our newsletter! These businesses generated 2010 sales of $1.9 billion*, representing an operational growth rate of 8 percent versus the prior year. J. Cypher was really the Coke of the sodas, the name brand synonymous with drug-eluting stents. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2011. The company will continue to focus on cardiovascular care through its Biosense Webster and Cordis businesses: Biosense Webster will continue to build and expand on its global leadership position in the $2.5 billion electrophysiology (EP) market, as an innovative provider of advanced cardiac diagnostic, therapeutic, and mapping tools. Gutierrez-Chico, J. L. et al. Professor Eduardo Sousa, M.D., who led the team carrying out the first-in-human trial in 1999 and the 10-year follow-up tests in 2009 in Sao Paolo, Brazil, said, "We are very pleased with these results. Dynamics in the DES market have changed considerably in recent years and continue to evolve in areas such as demand, pricing and reimbursement, and regulatory requirements for breakthrough new technologies. Nakamura, D. et al. The SYNERGY biodegradable polymer everolimus eluting coronary stent: porcine vascular compatibility and polymer safety study. Nat. Simultaneous intravascular ultrasound usage overcomes misinterpretation when evaluating lipid-rich plaques with optical frequency domain imaging ex vivo study. Barragan, P., Garitey, V., Mouneimne, K. & Rieu, R. Longitudinal compression behaviour of coronary stents: a bench-top comparative study. USA 100, 63946397 (2003). Pondicherry Institute of Medical Sciences, Pondicherry, India. Coll. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Kuramitsu, S. et al. 76% of the cases had diabetes. As the leader in EP navigation systems and ablation therapy, Biosense Webster has technology that includes the largest installed base of cardiac mapping navigation systems worldwide in leading hospitals and teaching institutions and a robust product pipeline. is a consultant for Abbott Vascular, Boston Scientific, Celonova, Cook Medical, Cordis, CSI, Edwards Lifescience, Lutonix Bard, Medtronic, OrbusNeich Medical, ReCore, Sinomededical Technology, Spectranetics, Surmodics, Terumo Corporation, W. L. Gore and Xeltis. Circulation 109, 701705 (2004). Poulsen, C. B. et al. JACC Cardiovasc. https://medical-dictionary.thefreedictionary.com/cordis, On March 2, after months of rumor and speculation, Johnson & Johnson finally sold its, Campbell Rogers, M.D., Chief Scientific Officer and Global Head R&D at, The Company explained that the "biggest variable driving these results" was the "disappointing performance" of the. According to the release, Cordis will stop making the once-groundbreaking Cypher sirolimus-eluting stent by the end of 2011 and is abandoning development plans for its Nevo sirolimus-eluting stent. For more than 50 years, Cordis Corporation, a Johnson & Johnson company, has been a worldwide leader in the development and manufacture of interventional vascular technology. Acute Cardiovascular Care, https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model. Cardiol. The experience with the Cypher Sirolimus-Eluting Coronary Stent (Cordis Corp., Miami Lakes, FL) at Arkansas Heart Hospital progressed from anxious anticipation to complete removal of the stent from inventory in a 6-month period. In experimental animal models, abluminally coated biodegradable-polymer DES and polymer-free DES allow earlier healing and faster return of endothelial barrier function than durable-polymer DES, owing to curtailed duration of drug residence in the arterial wall. 8, 12481260 (2015). Safety and efficacy of the next generation Resolute Onyx zotarolimus-eluting stent: primary outcome of the RESOLUTE ONYX core trial. The business will focus on access, diagnostic and therapeutic products for cardiology procedures, products to diagnose, access and treat lower extremity disease, and the INCRAFT Stent-Graft System, the company's new investigational device for treating abdominal aortic aneurysm (AAA). Heart Assoc. Medtronic showcased its presence across multiple market segments, including coronary stents, balloon catheters, interventional coronary catheters, diagnostic catheters and guidewires, as well as . This historic follow-up has revealed a sustained anti-proliferative effect of the CYPHER(R) stent by both angiography (in-stent late lumen loss of 0.10mm at 9 months as compared to 0.11 at 48 months) and IVUS examination (in stent % of obstruction of 1% at 4 months and 1,2,4, and 9 years). ", Campbell Rogers, M.D., Chief Scientific Officer and Global Head R&D at Cordis, said, "We continue to be gratified by the outstanding performance of CYPHER(R) compared with other drug-eluting stents. 59, 13621370 (2012). S.T., A.S., S.K., L.G. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. and A.V.F. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months versus aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. The site youre being redirected to is a branded pharmaceutical website. Am. In 76% of cases, iodixanol was used. J. Busch, R. et al. BRIDGEWATER, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced it will. Proximal mild edge dissection in the deployed stent was seen in 3 cases which were treated with stents. As the leader in EP navigation systems and ablation therapy, Biosense Webster has technology that includes the largest installed base of cardiac mapping navigation systems worldwide in leading hospitals and teaching institutions and a robust product pipeline. Lee, S. Y. et al. and A.V.F. Clin. Garg, S., Bourantas, C. & Serruys, P. W. New concepts in the design of drug-eluting coronary stents. The Cypher's one-time dominance has been eclipsed by the Xience/Promus everolimus-eluting devices, as well as the rise of other platforms, using other drugs. "Cordis has been a leader in establishing many markets including diagnostic and guiding catheters, bare metal and drug-eluting stents, carotid stenting, and treatment of peripheral vascular disease and arrhythmias. S.T., A.S., M.K., A.C., S.K., L.G., H.M., E.H., K.H.P., R.F., R.V. 30, 103109 (2019).

Hebrew Letter Nun Images, Utvs Kc Craigslist Atvs For Sale By Owner, What Holiday Has The Most Murders, Attacker Barbarian Assault, Terrell Isd Human Resources, Articles C